Idiotype vaccines for lymphoma therapy

Expert Review of Vaccines

Volumn 10, Issue 6, 2011, Pages 801-809

  Inogés, Susana ^a,b   De Cerio, Ascensión López Díaz ^a   Villanueva, Helena ^a   Soria, Elena ^a   Pastor, Fernando ^a   Bendandi, Maurizio ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

biological efficacy; clinical benefit; clinical efficacy; clinical trial; experimental therapy; idiotype; lymphoma; vaccine

Indexed keywords

BIOVAXID; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IDIOTYPE VACCINE; MITOXANTRONE; MYVAX; PREDNISONE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; FOLLICULAR LYMPHOMA; HUMAN; HYBRIDOMA; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

CANCER VACCINES; HUMANS; LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79959556138     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.44     Document Type: Review

References (53)

1. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 29(16), 2309-2324 (2010
2. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10(8), 550-560 (2010
3. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer 9(9), 675-681 (2009
4. Higano CS, Small EJ, Schellhammer P et al. Sipuleucel-T. Nat. Rev. Drug Discov. 9(7), 513-514 (2010
5. Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J. Natl Cancer Inst. 102(15), 1108-1110 (2010
6. Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev. Anticancer Ther. 1(1), 65-72 (2001 (Pubitemid 34679395)
7. McCarty H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br. J. Haematol. 123(5), 770-781 (2003 (Pubitemid 37533289)
8. Bendandi M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev. Vaccines 3(2), 163-170 (2004 (Pubitemid 38470526)
9. Bendandi M. Anti-idiotype vaccines for human follicular lymphoma. Leukemia 14(8), 1333-1339 (2000 (Pubitemid 30599311)
10. Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J. Clin. Invest. 113(10), 1498-1510 (2004 (Pubitemid 39071706)
11. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327(17), 1209-1215 (1992
12. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999 (Pubitemid 29474422)
13. Inogés S, Rodríguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98(18), 1292-1301 (2006 (Pubitemid 44530725)
14. López-Díaz de Cerio A, Inogés S. Future of idiotypic vaccination for B-cell lymphoma. Expert Rev. Vaccines 8(1), 43-50 (2009
15. Bendandi M, Marillonnet S, Kandzia R et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann. Oncol. 21(12), 2420-2427 (2010
16. Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89(1), 61-72 (1986 (Pubitemid 16079581)
17. Rodríguez-Calvillo M, Inogés S, López- Díaz de Cerio A, Zabalegui N, Villanueva H, Bendandi M. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit. Rev. Oncol. Hematol. 52(1), 1-7 (2004 (Pubitemid 39195240)
18. Inogés S, Rodríguez-Calvillo M, López- Díaz de Cerio A et al. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica 88(12), 1438-1440 (2003
19. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004 (Pubitemid 39273730)
20. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89(9), 3129-3135 (1997
21. Nelson EL, Li X, Hsu FJ et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88(2), 580-589 (1996 (Pubitemid 26240390)
22. Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev. 23(3), 137-142 (2009
23. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5), 1517-1526 (2002 (Pubitemid 34533020)
24. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22(23), 4717-4724 (2004
25. Weng WK, Czerwinski D, Levy R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 109(3), 951-953 (2007 (Pubitemid 46220638)
26. Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113(23), 5743-5746 (2009
27. Houot R, Levy R. Idiotype vaccination for lymphoma: moving towards optimisation. Leuk. Lymphoma 50(1), 1-2 (2009
28. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/ macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA 93(20), 10972-10977 (1996 (Pubitemid 26333102)
29. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345(8956), 1016-1020 (1995
30. + T cells. Blood 96(8), 2828-2833 (2000
31. Kannan S, Neelapu SS. Vaccination strategies in follicular lymphoma. Curr. Hematol. Malig. Rep. 4(4), 189-195 (2009
32. Barrios Y, Cabrera R, Yáñez R et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 87(4), 400-407 (2002 (Pubitemid 34297547)
33. Yáñez R, Barrios Y, Ruiz E, Cabrera R, Díaz-Espada F. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study. J. Immunother. 31(3), 310-312 (2008 (Pubitemid 351440998)
34. Bendandi M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration? Rev. Recent Clin. Trials 1(1), 67-74 (2006
35. Longo DL. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J. Natl Cancer Inst. 98(18), 1263-1265 (2006 (Pubitemid 44530722)
36. Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol. 13(1), 140-147 (1995
37. Inogés S, López-Díaz de Cerio A, Zabalegui N et al. Prolonged idiotypic vaccination against follicular lymphoma. Leuk. Lymphoma 50(1), 47-53 (2009
38. Bendandi M, Rodríguez-Calvillo M, Inogés S et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma 47(1), 29-37 (2006 (Pubitemid 43101721)
39. Inogés S, de Cerio AL, Sampol A et al. Stem cell transplant and idiotypic vaccination for B-cell malignancies. Curr. Top. Med. Chem. (2011) (In Press).
40. Neelapu SS, Kwak LW, Kobrin CB et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 11(9), 986-991 (2005 (Pubitemid 41294445)
41. Inogés S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M. Idiotype vaccines for human B-cell malignancies. Curr. Pharm. Des. 16(3), 300-307 (2010
42. Schuster SJ, Neelapu SS, Gause BL et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J. Clin. Oncol. 27(Suppl.), 18s (2009) (Abstract 2
43. Schuster SJ, Santos CF, Neelapu SS et al. Vaccination with IgM but not IgG idiotype prolongs remission duration in follicular lymphoma. Blood 116(22), (2010) (Abstract 429
44. McCormick AA, Kumagai MH, Hanley K et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl Acad. Sci. USA 96(2), 703-708 (1999 (Pubitemid 29061272)
45. McCormick AA, Reinl SJ, Cameron TI et al. Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J. Immunol. Methods 278(1-2), 95-104 (2003 (Pubitemid 37287600)
46. McCormick AA, Reddy S, Reinl SJ et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc. Natl Acad. Sci. USA 105(29), 10131-10136 (2008
47. Timmerman JM, Vose JM, Czerwinski DK et al. Tumor-specific recombinant idiotype immunization after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk. Lymphoma 50(1), 37-46 (2009
48. Levy R. Robertson MJ, Ganjoo K, Leonard JP, Vose J, Denney D. Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHLPresented at: 99th Annual Meeting of the American Association for Cancer Research San Diego, CA, USA, 12-16 April, 2008 (Abstract LB-204
49. López Díaz de Cerio A, Zabalegui N, Rodríguez- Calvillo M, Inogés S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 26(25), 3594-3602 (2007 (Pubitemid 46842706)
50. Redfern CH, Guthrie TH, Bessudo A et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J. Clin. Oncol. 24(19), 3107-3112 (2006 (Pubitemid 46638948)
51. Freedman A, Neelapu SS, Nichols C et al. Placebo-controlled Phase III trial of patient-specific immunotherapy with mitumprotimut-t and granulocyte- macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol. 27(18), 3036-3043 (2009
52. Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA Cancer J. Clin. 58(5), 305-317 (2008
53. Navarrete MA, Heining-Mikesch K, Schüler F et al. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood 117(5), 1483-1491 (2010).